| P50 | author | Nikolai G. Rainov | Q70270544 |
| P2093 | author name string | Volkmar Heidecke | |
| P2860 | cites work | Transferrin receptor on endothelium of brain capillaries | Q48602638 |
| | Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. | Q48727800 |
| | Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma | Q48829827 |
| | Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy | Q48962195 |
| | Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. | Q54607525 |
| | Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. | Q54635100 |
| | Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. | Q55475919 |
| | Cell proliferation and invasion in malignant gliomas. | Q55479040 |
| | Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. | Q55480258 |
| | Growth factors: The epidermal growth factor receptor gene and its product | Q59085677 |
| | The role of the diphtheria toxin receptor in cytosol translocation | Q68090289 |
| | Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy | Q70147645 |
| | Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR) | Q71099789 |
| | Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein | Q72120309 |
| | Brain tumors | Q73377286 |
| | Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy | Q77168507 |
| | Oncolytic viruses | Q78595329 |
| | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 |
| | Role of resection for newly diagnosed malignant gliomas | Q30311915 |
| | Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma | Q30431291 |
| | Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base | Q30660522 |
| | MR imaging of epilepsy: state of the art at 1.5 T and potential of 3 T. | Q30798226 |
| | Application of diffusion tensor imaging to magnetic-resonance-guided brain tumor resection | Q30799702 |
| | Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas | Q30885145 |
| | HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival | Q30954768 |
| | Diffusion tensor magnetic resonance imaging of brain tumors | Q30977014 |
| | Treatment of malignant glioma: a problem beyond the margins of resection | Q31907699 |
| | Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. | Q32157803 |
| | Surgery for gliomas | Q33185224 |
| | Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme | Q33382214 |
| | Targeted toxins | Q33847816 |
| | Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption | Q33873085 |
| | Replication-selective adenoviruses as oncolytic agents | Q33882702 |
| | Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma | Q33905047 |
| | Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 |
| | a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 |
| | Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas | Q34109937 |
| | The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study | Q34124333 |
| | Recombinant immunotoxins in targeted cancer cell therapy | Q34295821 |
| | Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 |
| | Biodegradable polymer implants to treat brain tumors | Q34328563 |
| | Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification | Q34350623 |
| | Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas | Q34428834 |
| | Reovirus therapy of tumors with activated Ras pathway | Q34479740 |
| | Genetically engineered human herpes simplex virus in the treatment of brain tumours. | Q34544859 |
| | Malignant gliomas | Q34678635 |
| | Pharmacokinetics of the carmustine implant | Q34696172 |
| | Vector delivery methods and targeting strategies for gene therapy of brain tumors | Q34729411 |
| | Oncolytic adenoviruses for treatment of brain tumours | Q35040863 |
| | Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment | Q35107972 |
| | Immunotoxin therapy for CNS tumor | Q35210454 |
| | Gene therapy for human malignant brain tumors. | Q35210470 |
| | Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside | Q35597936 |
| | A circularly permuted recombinant interleukin 4 toxin with increased activity | Q35602272 |
| | Recombinant toxins as novel therapeutic agents | Q35671038 |
| | Biology and treatment of gliomas | Q35674397 |
| | Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. | Q35740247 |
| | A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma | Q35894943 |
| | Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology | Q35939662 |
| | Advances in the biology of astrocytomas | Q35948857 |
| | Surgery for malignant gliomas: mechanistic reasoning and slippery statistics | Q36166582 |
| | Gene therapy for malignant glioma: current clinical status | Q36226708 |
| | Local treatment of malignant brain tumors using implantable chemotherapeutic polymers | Q36272210 |
| | Recombinant Toxins for Cancer Treatment | Q36533609 |
| | Immunotoxins and central nervous system neoplasia | Q36725728 |
| | Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy | Q37352605 |
| | Malignant glioma management | Q37848159 |
| | Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. | Q38288231 |
| | Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study | Q38557135 |
| | The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial | Q38562276 |
| | Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group | Q38573324 |
| | Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection | Q38606742 |
| | Immunotoxins: is there a clinical value? | Q40573244 |
| | Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer | Q40608630 |
| | Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses | Q40611932 |
| | In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures | Q40766959 |
| | Interleukin-4 and cancer therapy | Q40822480 |
| | Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach | Q40870377 |
| | In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme | Q41119145 |
| | Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm | Q41221688 |
| | Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system | Q41417789 |
| | The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. | Q41517544 |
| | Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir | Q41576545 |
| | A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. | Q42639115 |
| | Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy | Q42812425 |
| | Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy | Q43084440 |
| | Ark's gene therapy stumbles at the finish line | Q43138012 |
| | Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity | Q44016624 |
| | Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma | Q44376006 |
| | Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial | Q44422831 |
| | Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir | Q44466935 |
| | Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses | Q44654746 |
| | Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial | Q44697883 |
| | Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. | Q44697885 |
| | AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study | Q45127753 |
| | Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas | Q45325311 |
| | Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals | Q45714399 |
| | A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. | Q45739549 |
| | A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma | Q45752309 |
| | A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group | Q45862712 |
| | Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study | Q45867285 |
| | Gene therapy in brain tumours: implications of the size of glioblastoma on its curability | Q45882855 |
| | HSV1716 persistence in primary human glioma cells in vitro | Q45888466 |
| | Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies | Q46339509 |
| | Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial | Q46947774 |
| | Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia | Q46973724 |
| | Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. | Q48088104 |
| | Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig | Q48133104 |
| | Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice | Q48164496 |
| | Malignant glioma: patterns of failure following individually tailored limited volume irradiation | Q48179804 |
| | Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma | Q48209763 |
| | Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin | Q48536258 |
| | Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors | Q48587395 |
| | Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells | Q48587406 |
| P433 | issue | 1 | |
| P304 | page(s) | 5-28 | |
| P577 | publication date | 2011-02-12 | |
| P1433 | published in | Sultan Qaboos University medical journal | Q26842237 |
| P1476 | title | Clinical development of experimental therapies for malignant glioma | |
| P478 | volume | 11 | |